<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816841</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-08095</org_study_id>
    <secondary_id>NCI-2012-02017</secondary_id>
    <nct_id>NCT01816841</nct_id>
  </id_info>
  <brief_title>Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care</brief_title>
  <official_title>The Role of Direct Visual Fluorescence in Oral Examination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies direct visual fluorescence in finding oral cancer in high-risk
      patients and patients undergoing routine dental care. Diagnostic procedures, such as direct
      visual fluorescence, may help find and diagnose oral cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the diagnostic benefit of the VELscope (direct visual fluorescence) inspection
      in oral examination.

      II. Efficacy of the VELscope in identifying dysplastic (premalignant) and malignant oral
      mucosal lesions and in discriminating these lesions from common benign tissue changes.

      III. Accuracy of clinical judgment versus VELscope findings. IV. Ability of the VELscope to
      identify lesions or extent of lesions beyond what is clinically apparent.

      OUTLINE:

      Patients undergo conventional oral examination (COE) followed by direct visual fluorescence
      examination (DVFE). Patients with tissue abnormalities found by COE or DVFE undergo scalpel
      biopsy within 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2008</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of DVFE compared to visual inspection by conventional oral examination alone</measure>
    <time_frame>At the time of examination</time_frame>
    <description>Will be evaluated by calculating sensitivity and specificity and their corresponding exact 95% confidence intervals. Association between the two techniques will be assessed using the simple kappa statistic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences between lesional margins identified by COE and DVFE</measure>
    <time_frame>At the time of examination</time_frame>
    <description>Will be evaluated using the dependent t-test. In the event that the parametric requirements of this test are not met, the Wilcoxon, matched-pairs, signed-ranks test will be used.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">283</enrollment>
  <condition>Lip and Oral Cavity Squamous Cell Carcinoma</condition>
  <condition>Oral Cavity Verrucous Carcinoma</condition>
  <condition>Stage 0 Lip and Oral Cavity Cancer</condition>
  <condition>Tongue Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (COE and DVFE)- Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm I - Patients undergo COE followed by DVFE. Patients with tissue abnormalities found by COE or DVFE undergo biopsy within 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II - Comparison of surgical margins using COE vs. DVFE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparison of surgical margins using COE vs. DVFE</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fluorescence imaging</intervention_name>
    <description>Undergo DVFE</description>
    <arm_group_label>Diagnostic (COE and DVFE)- Arm I</arm_group_label>
    <arm_group_label>Arm II - Comparison of surgical margins using COE vs. DVFE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Undergo scalpel biopsy</description>
    <arm_group_label>Diagnostic (COE and DVFE)- Arm I</arm_group_label>
    <arm_group_label>Arm II - Comparison of surgical margins using COE vs. DVFE</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>examination</intervention_name>
    <description>Undergo COE</description>
    <arm_group_label>Diagnostic (COE and DVFE)- Arm I</arm_group_label>
    <arm_group_label>Arm II - Comparison of surgical margins using COE vs. DVFE</arm_group_label>
    <other_name>Exam</other_name>
    <other_name>Medical Assessment</other_name>
    <other_name>Medical Exam</other_name>
    <other_name>Medical Examination</other_name>
    <other_name>Medical Inspection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Comparison of surgical margins by COE vs. DVFE</intervention_name>
    <description>Surgical margin determination using DVFE</description>
    <arm_group_label>Arm II - Comparison of surgical margins using COE vs. DVFE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIGH-RISK POPULATION:

          -  33 consecutive consenting patients presenting to The Ohio State University James
             Cancer Hospital Otolaryngology Department with a suspicious oral lesion or prior
             biopsy-confirmed epithelial dysplasia (mild, moderate, severe), carcinoma in situ
             (CIS), or squamous cell carcinoma (SCC) will be recruited; adult patients presenting
             for initial evaluation for treatment planning and/or presenting for follow-up
             appointments monitoring for recurrence will be eligible to participate

          -  GENERAL POPULATION:

          -  250 consecutive consenting patients presenting to The Ohio State University College of
             Dentistry for routing dental care will be recruited; adult patients presenting to the
             screening clinic for initial oral evaluation will be eligible to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin McNamara</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ohio State University Comprehensive Cancer Center</last_name>
    <phone>1-800-293-5066</phone>
    <email>Jamesline@osumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Kalmar, DMD PhD</last_name>
    <phone>614-292-6577</phone>
    <email>kalmar.7@osu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin McNamara</last_name>
    </contact>
    <investigator>
      <last_name>Kristin McNamara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Kristin McNamara</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Direct Visual Fluorescense</keyword>
  <keyword>Oral Examination</keyword>
  <keyword>oral cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Verrucous</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Tongue Neoplasms</mesh_term>
    <mesh_term>Lip Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

